about
Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods studyDrug therapy persistence and stroke recurrenceRifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysisConcordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer.Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion.Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review.Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patientsComparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.Disparity implications of Medicare eligibility criteria for medication therapy management services"Ten commandments" for conducting comparative effectiveness research using "real-world data".Developing a collaborative study protocol for combining payer-specific data and clinical trials for CER.Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials.From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerComparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?Germinal center B-cells resist transformation by Kras independently of tumor suppressor ArfRacial variation in the cost-effectiveness of chemotherapy for prostate cancer.The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population.A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting.Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study.Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.Patient-centeredness in the design of clinical trialsDementia severity and the longitudinal costs of informal care in the Cache County populationWhite paper: value of specialty certification in pharmacy.Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites.Intervention for decreasing excessive acetaminophen use in Pennsylvania Medicaid recipients.Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes researchVariability and growth in spending for outpatient specialty pharmaceuticals.Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancerRecommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients.Personalized Strategies to Activate and Empower Patients in Health Care and Reduce Health Disparities.Cost-of-illness studies : a review of current methods.Health plans' strategies for managing outpatient specialty pharmaceuticals.Benefits Improvement and Protection Act's impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal diseasePatient engagement and shared decision-making: What do they look like in neurology practice?Principles of economics crucial to pharmacy students' understanding of the prescription drug market.A survey of nephrologists' views on preemptive transplantation.Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
P50
Q27309115-35F496FA-B568-4F10-89E2-77E3B2C6C1EDQ28218862-305FC4A7-C8ED-42E8-BFF7-E96491C5C305Q28480467-9431CCE6-AB93-4DFE-B197-73E04A5B1631Q30725083-523CB2C7-0ED2-4F1F-BE89-F58267CA7BFDQ31130672-F614D89F-0A37-47C7-A5CB-3A01E7B2DBAEQ31153721-EA690854-0B8B-464B-B78A-4B992713DEC2Q33405177-4BEEA6F8-4F20-47AB-9788-A99B6AB8154CQ33574428-C595851F-083F-4BEB-A3A5-6423D5FC8001Q33937296-F4789846-3394-49F0-83CF-FB1E63734E75Q33970042-48BB4571-4108-4177-AECF-76479F4B26BDQ33989357-7B8C9720-797B-4193-B110-E9C85EA8747DQ34022273-BF0E26EE-4F74-4136-8631-788CD19DE96BQ34072301-81B21518-6DB5-4F15-BB83-850C077D226AQ34072311-988AD259-DFA1-49EE-9D0F-D8057CCCDE48Q34137236-80E95B17-A944-4CA7-8F0D-810766E876BCQ34509675-2D1FD858-A41F-4D2B-84F1-EAE83537DBB0Q34725854-80F395CC-7514-43D6-BC99-93505F1E7C85Q34795181-D3344B88-7998-4377-A577-C40CEF00F3A5Q34974133-5D14F786-BF89-4F59-9B89-347A0334F9BFQ35175079-0DDCCF5C-4EA4-4764-BF3C-3CA87C7BB484Q35453836-29749F10-E35D-4EFA-AD11-FE173690F887Q35552333-6B001C44-ED28-4DAC-A5A7-670243E3AA1FQ35749531-F5C8B60E-40A3-48BC-BB11-72A481A7F02BQ35835715-312E1B0A-F8BA-4D45-A50C-41B4ECAF1BCFQ35864658-4C868E01-85AB-4A8F-88CA-0CBDEB4E65ACQ35923898-E483B73B-973B-41CD-BD3C-B6E9770470C8Q35955098-6B6A5F49-00F1-4327-A6A8-27A4798CF1C5Q35973989-FF91A3FF-F621-44EE-8E99-8356B7ADD040Q36160519-1F961049-C3F4-44C6-97DF-619B1D1078B5Q36191569-DA7EA773-D4E6-422E-B6F7-A2E1A6851616Q36251473-758F0A1B-33FB-49C1-8BF5-3B1C8E7D1F0CQ36314941-24A346D8-BD5D-49DC-8DD9-67B14AC79A64Q36378339-A18A434D-EC4D-4F0B-B195-3C60DF91D6ACQ36581690-7D3AD8C3-236B-4707-9334-07F7ADFF5576Q36591077-0275F2AF-3796-40DA-BC16-25FC0149D005Q36592263-CDC83660-B93F-4721-8E84-7D8D4847F37AQ36789892-767737BA-8A8F-48F4-868B-0E39E1D964F0Q36829544-917EE903-55CF-486D-A09A-3C462CBF15A4Q36947370-5A1063C7-D6AF-4E19-B24C-1491028CD54BQ36948710-335A14DE-3D2C-4C83-86CA-A37FBCE6C8C4
P50
description
researcher
@en
wetenschapper
@nl
name
C. Daniel Mullins
@en
Mullins CD
@nl
type
label
C. Daniel Mullins
@en
Mullins CD
@nl
altLabel
Mullins CD
@en
prefLabel
C. Daniel Mullins
@en
Mullins CD
@nl
P106
P31
P496
0000-0003-4322-2490